Extraordinary popular delusions and the madness of crowds: Puncturing the epoetin bubble-lessons for the future

Nephrology Dialysis Transplantation

Volumn 26, Issue 1, 2011, Pages 24-28

  Goldsmith, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anaemia; epoetin; mortality

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; GLOMERULUS FILTRATION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANEMIA; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; SURVIVAL RATE;

EID: 78650655472     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq577     Document Type: Article

References (28)

1. Charles Mackay's Extraordinary Popular Delusions and the Madness of Crowds: a modern-day interpretation of a finance classic (infinite success series). London: Infinite Ideas Ltd., 2004; ISBN-13: 978-1905940912
2. Pfeffer MA, Burdmann EA, Chen CY et al. TREAT investigators: a trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 1-14
3. Goldsmith D. 2009: a requiem for rHuEPOs-but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010; 5: 929-935
4. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythro-poietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
5. Mendelssohn DC, Yeates KE, Ethier J et al. DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Canada. Nephrol News Issues 2007; 21: 69-70
6. Thamer M, Zhang Y, Kaufman J et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 2007; 297: 1667-1674
7. http://en.wikiquote.org/wiki/Donald-Rumsfeld. Department of US Defence briefing, 12 February,2002
8. Khankin EV, Mutter WP, Tamez H et al. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS ONE 2010; 5: e9246
9. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010; 21: 2-6
10. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223
11. Besarab A, Bolton WK, Browne JK. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
12. National Kidney Foundation. KDOQI Clinical Practice Guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30: S192-S240
13. Drüeke TB, Locatelli F, Clyne N et al. CREATE investigators: normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
14. Singh AK, Szczech L, Tang KL et alCHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
15. Goldsmith DJA, Covic A. Time to reconsider evidence of anaemia treatment-essential safety assessment. Nephrol Dial Transplant 2010; 25: 1734-1737
16. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythro-poiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33
17. Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: bursting the hemoglobin bubble. Ann Intern Med 2010; 153: 53-55
18. Locatelli F, Aljama P, Canaud B et alOn behalf of the Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
19. van Biesen W, Vanholder R. When to start dialysis: tunnel vision induced by numbers? Nephrol Dial Transplant 2010; 25: 2405-2407
20. Agarwal A. Individualizing decision making: resurrecting the doctor- patient relationship in the anemia debate. Clin J Am Soc Nephrol 2010; 5: 1340-1346
21. Karpinski M, Pochinco D, Dembinski I et al. Leukocyte reductions of red cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-824
22. Aalten J, Bemelman FJ, van den Berg-Loonen EM et al. Pre-kidney blood transfusions do not improve transplantation outcome: a Dutch national study. Nephrol Dial Trasplant 2009; 24: 2559-2566
23. Ranavan R, Udayaraj U, Ansell D et al. Variation between centres in access to renal transplantation in UK: longitudinal cohort study. Br Med J 2010; 341: c3451
24. Coyne D. Its time to compare anemia management strategies. Clin J Am Soc Nephrol 2010; 5: 740-742
25. http://www.fiercepharma.com/pages/fastest-growing-therapeutic-classes- sales.
26. Goldsmith D, Covic A. Blood pressure control in CKD stage 5D patients-are we more or less certain what to do in 2009? Nephrol Dial Transplant 2009; 24: 3597-3601
27. Navaneethan SD, Palmer SC, Craig JC et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54: 619-637
28. Covic A, Voroneanu L, Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function-are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010; 116: c187-c195